MedTrace Logo

Yiqi Huoxue Demolition and Recipes on Recovery Stage of Cerebral Infarction

NCT02846207 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 360

Last updated 2018-02-12

No results posted yet for this study

Summary

This clinical research is based on the fundamentals of using Chinese medicine, which will improve Qi and promote blood circulation, to treat patients in the recuperating stages of cerebral infarction with deficiency in Qi and blood stasis syndrome. By assimilating Chinese medical theory, this research aims to study the biological basics of the stroke and the cause for the deficiency in Qi and blood stasis syndrome; explore the therapeutic mechanism of the treatment methods; as well as ascertaining the relationship between Qi, blood and blood vessels.

Conditions

  • Cerebral Infarction

Interventions

DRUG

Yiqi huoxue

Buyang Huanwu demolition, which includes: Astragalus 60g, Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.

DRUG

Yiqi group

Astragalus 60g.Oral administration, twice one day, for 12weeks.

DRUG

Huoxue group

Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.

DRUG

placebo

Dextrin,oral administration, twice one day, for 12weeks.

Sponsors & Collaborators

  • Xingtai People's Hospital

    collaborator OTHER

  • Dongfang Hospital Beijing University of Chinese Medicine

    lead OTHER

Principal Investigators

  • Liu Xiangzhe, PHD,MD · The First Affiliated Hospital of Henan University of Traditional Chinese Medicine

  • Wang Jianhua, PHD,MD · Xingtai People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
FACTORIAL

Eligibility

Min Age
35 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02846207 on ClinicalTrials.gov